The content on this site is intended for healthcare professionals only
Prof Lancet speaks with ecancertv at ASH 2016 about CPX-351, a liposomal delivery of cytarabine and daunorubicin, for elderly patients with advanced AML.
Compared to the 7 3 schedule, he describes this subgroup as achieving better outcomes with acceptable toxicity profiles, and considers how CPX-351 might come to be used in other patient subgroups based on these results.
Video of the press conference in which these results were announced is available here, and more detail is available through ecancer news here.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
